

Tool Kit for Minimizing the Burden of Hidradenitis Suppurativa: Systemic Treatments for Moderate-to-Severe Disease

Resource	Address
Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: topical, intralesional, and systemic medical management. <i>J Am Acad Dermatol</i> . 2019;81:91-101.	https://pubmed.ncbi.nlm.nih.gov/30872149/
Andersen PL, Nielsen RM, Sigsgaard V, Jemec GBE, Riis PT. Body image quality of life in patients with hidradenitis suppurativa compared with other dermatological disorders. <i>Acta Derm Venereol</i> . 2020;100:adv00107.	https://pubmed.ncbi.nlm.nih.gov/32201901/
Deckers IE, Kimball AB. The handicap of hidradenitis suppurativa. <i>Dermatol Clin</i> . 2016;34:17-22.	https://pubmed.ncbi.nlm.nih.gov/26617353/
Frew JW. Autoantibody-mediated macrophage responses provide the missing link between innate and adaptive immune dysfunction in hidradenitis suppurativa. <i>J Invest Dermatol</i> . 2022;142:747-749.	https://pubmed.ncbi.nlm.nih.gov/34716008/
Frew JW, Hawkes JE, Krueger JG. A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa. <i>F1000Res</i> . 2018;7:1923.	https://pubmed.ncbi.nlm.nih.gov/31281635/
Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjust population analysis of prevalence estimates for hidradenitis suppurativa in the United States. <i>JAMA Dermatol</i> . 2017;153:760-764.	https://pubmed.ncbi.nlm.nih.gov/28492923/
Garg A, Malviya N, Strunk A, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. <i>J Am Acad Dermatol</i> . 2022;86:1092-1101.	https://pubmed.ncbi.nlm.nih.gov/33493574/
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. <i>J Am Acad Dermatol</i> . 2020;82:1045-1058.	https://pubmed.ncbi.nlm.nih.gov/31604104/
Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. <i>Dermatology</i> . 2021;237:81-96.	https://pubmed.ncbi.nlm.nih.gov/31645040/
Ingram JR. The epidemiology of hidradenitis suppurativa. <i>Br J Dermatol</i> . 2020;183:990-998.	https://pubmed.ncbi.nlm.nih.gov/32880911/

Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. <i>Br J Dermatol</i> . 2019;180:1009-1017.	https://pubmed.ncbi.nlm.nih.gov/30552762/
Jørgensen AHR, Holm JG, Ghazanfar MN, Yao Y, Ring HC, Thomsen SF. Factors affecting quality of life in patients with hidradenitis suppurativa. <i>Arch Dermatol Res</i> . 2020;312:427-436.	https://pubmed.ncbi.nlm.nih.gov/31848682/
Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. <i>Dermatology</i> . 2016;232:687-691.	https://pubmed.ncbi.nlm.nih.gov/28052274/
Kurzen H, Kurokawa I, Jemec GBE, et al. What causes hidradenitis suppurativa? <i>Exp Dermatol</i> . 2008;17:455-456.	https://pubmed.ncbi.nlm.nih.gov/18400064/
Navrazhina K, Garcet S, Zheng X, Hur HB, Frew JW, Krueger JG. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. <i>J Allergy Clin Immunol</i> . 2022;149:135-144.e12.	https://pubmed.ncbi.nlm.nih.gov/34081946/
Rondags A, van Straalen KR, van Hasselt JR, et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment. <i>Br J Dermatol</i> . 2019;180:1214-1220.	https://pubmed.ncbi.nlm.nih.gov/30512186/
Savage KT, Singh V, Patel ZS, et al. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. <i>J Am Acad Dermatol</i> . 2021;85:187-199.	https://pubmed.ncbi.nlm.nih.gov/32950543/
Thorlacius L, Cohen AD, Gislason GH, Jemec GBE, Egeberg A. Increased suicide risk in patients with hidradenitis suppurativa. <i>J Invest Dermatol</i> . 2018;138:52-57.	https://pubmed.ncbi.nlm.nih.gov/28942360/
Vekic DA, Cains GD. Hidradenitis suppurativa—management, comorbidities and monitoring. <i>Aust Fam Physician</i> . 2017;46:584-588.	https://pubmed.ncbi.nlm.nih.gov/28787558/
Wieczorek M, Walecka I. Hidradenitis suppurativa—known and unknown disease. <i>Reumatologia</i> . 2018;56:337-339.	https://pubmed.ncbi.nlm.nih.gov/30647478/